Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications

Clinical and Experimental Allergy

Volumn 47, Issue 2, 2017, Pages 161-175

  Robinson, D ^a   Humbert, M ^b   Buhl, R ^c   Cruz, A A ^d   Inoue, H ^e   Korom, S ^f   Hanania, N A ^g   Nair, P ^h  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^e KAGOSHIMA UNIVERSITY   (Japan)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; NITRIC OXIDE; TRANSCRIPTION FACTOR RUNX2; AUTACOID; CYTOKINE;

ADAPTIVE IMMUNITY; ASTHMA; CYTOKINE RELEASE; DISEASE CLASSIFICATION; DISEASE SEVERITY; EOSINOPHIL; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INNATE IMMUNITY; NOMENCLATURE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SPUTUM; ANIMAL; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TH2 CELL;

ANIMALS; ASTHMA; BIOMARKERS; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TH2 CELLS;

EID: 85010908346     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12880     Document Type: Review

References (177)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention – updated 2016. 2016. Available at: http://ginasthma.org/gina-reports/ (Last accessed 13 January 2017).
2. Reddel HK, Bateman ED, Becker A et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J 2015; 46:622–39.
3. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368:804–13.
4. Corren J. Asthma phenotypes and endotypes: an evolving paradigm for classification. Discov Med 2013; 15:243–9.
5. Lotvall J, Akdis CA, Bacharier LB et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127:355–60.
6. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. Clin Exp Allergy 2012; 42:650–8.
7. Green RH, Pavord I. Stability of inflammatory phenotypes in asthma. Thorax 2012; 67:665–7.
8. Moore WC, Bleecker ER. Asthma heterogeneity and severity-why is comprehensive phenotyping important? Lancet Respir Med 2014; 2:10–1.
9. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343–73.
10. Johansson SG, Bieber T, Dahl R et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832–6.
11. Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184–90.
12. Barnes PJ. Intrinsic asthma: not so different from allergic asthma but driven by superantigens? Clin Exp Allergy 2009; 39:1145–51.
13. Humbert M, Durham SR, Ying S et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against “intrinsic” asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996; 154:1497–504.
14. Humbert M, Menz G, Ying S et al. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999; 20:528–33.
15. Haldar P, Pavord ID. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol 2007; 119:1043–52.
16. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11:54–61.
17. Gibson PG, Fujimura M, Niimi A. Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax 2002; 57:178–82.
18. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med 2013; 19:977–9.
19. McGrath KW, Icitovic N, Boushey HA et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012; 185:612–9.
20. Green RH, Brightling CE, Woltmann G et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57:875–9.
21. Green BJ, Wiriyachaiporn S, Grainge C et al. Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PLoS One 2014; 9:e100645.
22. Nair P, Aziz-Ur-Rehman A, Radford K. Therapeutic implications of ‘neutrophilic asthma’. Curr Opin Pulm Med 2015; 21:33–8.
23. Gao P, Gibson PG, Baines KJ et al. Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1beta. Respir Res 2015; 16:5.
24. Simpson JL, Daly J, Baines KJ et al. Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma. Eur Respir J 2016; 47:792–800.
25. Nair P, Gaga M, Zervas E et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 2012; 42:1097–103.
26. O'Byrne PM, Metev H, Puu M et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2016; 4:797–806.
27. Mukherjee M, Svenningsen S, Nair P. Glucocorticosteroid subsensitivity and asthma severity. Curr Opin Pulm Med 2017; 23:78–88.
28. Mosmann TR, Cherwinski H, Bond MW et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136:2348–57.
29. Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol 2015; 15:57–65.
30. Spellberg B, Edwards JE Jr. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 2001; 32:76–102.
31. Robinson DS, Hamid Q, Ying S et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298–304.
32. Woodruff PG, Modrek B, Choy DF et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388–95.
33. Baines KJ, Simpson JL, Wood LG et al. Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. J Allergy Clin Immunol 2011; 127:153–60.
34. Motomura Y, Kitamura H, Hijikata A et al. The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4 + T cells. Nat Immunol 2011; 12:450–9.
35. Barlow JL, McKenzie AN. Type-2 innate lymphoid cells in human allergic disease. Curr Opin Allergy Clin Immunol 2014; 14:397–403.
36. Christianson CA, Goplen NP, Zafar I et al. Persistence of asthma requires multiple feedback circuits involving type 2 innate lymphoid cells and IL-33. J Allergy Clin Immunol 2015; 136:59–68.
37. Kim BS, Siracusa MC, Saenz SA et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 2013; 5:170ra16.
38. Lee JB, Chen CY, Liu B et al. IL-25 and CD4(+) TH2 cells enhance type 2 innate lymphoid cell-derived IL-13 production, which promotes IgE-mediated experimental food allergy. J Allergy Clin Immunol 2016; 137:1216–25.
39. Chen Y, Thai P, Zhao YH et al. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem 2003; 278:17036–43.
40. Cosmi L, Liotta F, Maggi E et al. Th17 cells: new players in asthma pathogenesis. Allergy 2011; 66:989–98.
41. Kao CY, Chen Y, Thai P et al. IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J Immunol 2004; 173:3482–91.
42. Leite-de-Moraes M, Hammad H, Dy M. Crosstalk between innate and adaptive cells on allergic process. J Allergy (Cairo) 2012; 2012:720568.
43. Oliphant CJ, Barlow JL, McKenzie AN. Insights into the initiation of type 2 immune responses. Immunology 2011; 134:378–85.
44. Noben-Trauth N, Hu-Li J, Paul WE. IL-4 secreted from individual naive CD4 + T cells acts in an autocrine manner to induce Th2 differentiation. Eur J Immunol 2002; 32:1428–33.
45. van Panhuys N, Tang SC, Prout M et al. In vivo studies fail to reveal a role for IL-4 or STAT6 signaling in Th2 lymphocyte differentiation. Proc Natl Acad Sci USA 2008; 105:12423–8.
46. Rael EL, Lockey RF. Interleukin-13 signaling and its role in asthma. World Allergy Organ J 2011; 4:54–64.
47. Takayama G, Arima K, Kanaji T et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006; 118:98–104.
48. van Rijt L, von Richthofen H, Van Ree R. Type 2 innate lymphoid cells: at the cross-roads in allergic asthma. Semin Immunopathol 2016; 38:483–96.
49. Klein Wolterink RG, Kleinjan A, van Nimwegen M et al. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur J Immunol 2012; 42:1106–16.
50. Erazo A, Kutchukhidze N, Leung M et al. Unique maturation program of the IgE response in vivo. Immunity 2007; 26:191–203.
51. Gibeon D, Menzies-Gow AN. Targeting interleukins to treat severe asthma. Expert Rev Respir Med 2012; 6:423–39.
52. Tang Y, Zeng Y, Li Y. [Study on mutations of beta chain of high-affinity IgE receptor gene in people of Han nationality of southern China]. Zhonghua Jie He He Hu Xi Za Zhi 2001; 24:142–4.
53. Oh CK, Raible D, Geba GP, Molfino NA. Biology of the interleukin-9 pathway and its therapeutic potential for the treatment of asthma. Inflamm Allergy Drug Targets 2011; 10:180–6.
54. Parker JM, Oh CK, LaForce C et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med 2011; 11:14.
55. Ramalingam TR, Pesce JT, Sheikh F et al. Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain. Nat Immunol 2008; 9:25–33.
56. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004; 22:789–815.
57. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003; 111:677–90.
58. Leigh R, Ellis R, Wattie J et al. Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice? Am J Respir Crit Care Med 2004; 170:851–6.
59. Fichtner-Feigl S, Strober W, Kawakami K et al. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006; 12:99–106.
60. Komai M, Tanaka H, Masuda T et al. Role of Th2 responses in the development of allergen-induced airway remodelling in a murine model of allergic asthma. Br J Pharmacol 2003; 138:912–20.
61. Grunig G, Warnock M, Wakil AE et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282:2261–3.
62. Scheerens H, Arron J, Choy D et al. Lebrikizumab treatment reduces serum periostin levels in asthma patients with elevated baseline levels of periostin. Am J Respir Crit Care Med 2012; 185:A3960.
63. Chen W, Sivaprasad U, Gibson AM et al. IL-13 receptor alpha2 contributes to development of experimental allergic asthma. J Allergy Clin Immunol 2013; 132:951–8.
64. Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 2000; 105:1063–70.
65. Grunstein MM, Hakonarson H, Leiter J et al. IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2002; 282:L520–8.
66. Risse PA, Jo T, Suarez F et al. Interleukin-13 inhibits proliferation and enhances contractility of human airway smooth muscle cells without change in contractile phenotype. Am J Physiol Lung Cell Mol Physiol 2011; 300:L958–66.
67. Tanabe T, Fujimoto K, Yasuo M et al. Modulation of mucus production by interleukin-13 receptor alpha2 in the human airway epithelium. Clin Exp Allergy 2008; 38:122–34.
68. Zhu Z, Homer RJ, Wang Z et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103:779–88.
69. Pope SM, Brandt EB, Mishra A et al. IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 2001; 108:594–601.
70. de Waal MR, Abrams JS, Zurawski SM et al. Differential regulation of IL-13 and IL-4 production by human CD8 + and CD4 + Th0, Th1 and Th2 T cell clones and EBV-transformed B cells. Int Immunol 1995; 7:1405–16.
71. Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 2007; 119:1303–10.
72. Sakuishi K, Oki S, Araki M et al. Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol 2007; 179:3452–62.
73. Warren HS, Kinnear BF, Phillips JH, Lanier LL. Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and IL-12. J Immunol 1995; 154:5144–52.
74. Takatsu K. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci 2011; 87:463–85.
75. Menzies-Gow A, Flood-Page P, Sehmi R et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003; 111:714–9.
76. Sanderson CJ. The biological role of interleukin 5. Int J Cell Cloning 1990; 8(Suppl. 1):147–53.
77. Sitkauskiene B, Johansson AK, Sergejeva S et al. Regulation of bone marrow and airway CD34 + eosinophils by interleukin-5. Am J Respir Cell Mol Biol 2004; 30:367–78.
78. Wardlaw AJ. Eosinophil trafficking in asthma. Clin Med 2001; 1:214–8.
79. Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 2009; 21:1303–9.
80. Louahed J, Kermouni A, Van Snick J, Renauld JC. IL-9 induces expression of granzymes and high-affinity IgE receptor in murine T helper clones. J Immunol 1995; 154:5061–70.
81. Zhou Y, McLane M, Levitt RC. Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma. Respir Res 2001; 2:80–4.
82. Cheng G, Arima M, Honda K et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med 2002; 166:409–16.
83. Kearley J, Erjefalt JS, Andersson C et al. IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. Am J Respir Crit Care Med 2011; 183:865–75.
84. Steenwinckel V, Louahed J, Orabona C et al. IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. J Immunol 2007; 178:3244–51.
85. Matsumoto H. Serum periostin: a novel biomarker for asthma management. Allergol Int 2014; 63:153–60.
86. Kim MA, Shin YS, Pham LD, Park HS. Adult asthma biomarkers. Curr Opin Allergy Clin Immunol 2014; 14:49–54.
87. Dweik RA, Boggs PB, Erzurum SC et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184:602–15.
88. Voraphani N, Gladwin MT, Contreras AU et al. An airway epithelial iNOS-DUOX2-thyroid peroxidase metabolome drives Th1/Th2 nitrative stress in human severe asthma. Mucosal Immunol 2014; 7:1175–85.
89. Berry MA, Shaw DE, Green RH et al. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy 2005; 35:1175–9.
90. Scott M, Raza A, Karmaus W et al. Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. Thorax 2010; 65:258–62.
91. Vijverberg SJ, Koenderman L, Koster ES et al. Biomarkers of therapy responsiveness in asthma: pitfalls and promises. Clin Exp Allergy 2011; 41:615–29.
92. National Heart Lung and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.pdf (Last accessed 13 January 2017).
93. Genentech I. Xolair Prescribing Information. 2016. Available at: http://www.gene.com/gene/products/information/pdf/xolair-prescribing.pdf (Last accessed 13 January 2017).
94. Greenberger PA, Bush RK, Demain JG et al. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract 2014; 2:703–8.
95. Wadsworth S, Sin D, Dorscheid D. Clinical update on the use of biomarkers of airway inflammation in the management of asthma. J Asthma Allergy 2011; 4:77–86.
96. Nair P. What is an “eosinophilic phenotype” of asthma? J Allergy Clin Immunol 2013; 132:81–3.
97. National Institute for Health and Care Excellence. Mepolizumab for treating severe refractory eosinophilic asthma. 2016. Available at: https://www.nice.org.uk/guidance/GID-TAG519/documents/html-content-3 (Last accessed 13 January 2017).
98. Pavord ID, Korn S, Howarth P et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651–9.
99. Schleich FN, Manise M, Sele J et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13:11.
100. Turner MO, Hussack P, Sears MR et al. Exacerbations of asthma without sputum eosinophilia. Thorax 1995; 50:1057–61.
101. Jayaram L, Pizzichini MM, Cook RJ et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27:483–94.
102. O'Byrne PM. Therapeutic strategies to reduce asthma exacerbations. J Allergy Clin Immunol 2011; 128:257–63.
103. Mukherjee M, Nair P. Blood or sputum eosinophils to guide asthma therapy? Lancet Respir Med 2015; 3:824–5.
104. Guerra S, Sherrill DL, Kurzius-Spencer M et al. The course of persistent airflow limitation in subjects with and without asthma. Respir Med 2008; 102:1473–82.
105. ten Brinke A, Zwinderman AH, Sterk PJ et al. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164:744–8.
106. Tubby C, Harrison T, Todd I, Fairclough L. Immunological basis of reversible and fixed airways disease. Clin Sci (Lond) 2011; 121:285–96.
107. Ali Z, Dirks CG, Ulrik CS. Long-term mortality among adults with asthma: a 25-year follow-up of 1,075 outpatients with asthma. Chest 2013; 143:1649–55.
108. Possa SS, Leick EA, Prado CM et al. Eosinophilic inflammation in allergic asthma. Front Pharmacol 2013; 4:46.
109. Bacci E, Cianchetti S, Ruocco L et al. Comparison between eosinophilic markers in induced sputum and blood in asthmatic patients. Clin Exp Allergy 1998; 28:1237–43.
110. Schleich FN, Chevremont A, Paulus V et al. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 2014; 44:97–108.
111. Fowler SJ, Tavernier G, Niven R. High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma. J Allergy Clin Immunol 2015; 135:822–4.
112. Hastie AT, Moore WC, Li H et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 2013; 132:72–80.
113. Wagener AH, de Nijs SB, Lutter R et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015; 70:115–20.
114. Jia G, Erickson RW, Choy DF et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012; 130:647–54.
115. Sidhu SS, Yuan S, Innes AL et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010; 107:14170–5.
116. Woodruff PG, Boushey HA, Dolganov GM et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007; 104:15858–63.
117. Blanchard C, Mingler MK, McBride M et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 2008; 1:289–96.
118. Sehra S, Yao W, Nguyen ET et al. Periostin regulates goblet cell metaplasia in a model of allergic airway inflammation. J Immunol 2011; 186:4959–66.
119. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088–98.
120. Hanania NA, Noonan M, Corren J et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 2015; 70:748–56.
121. Caswell-Smith R, Hosking A, Cripps T et al. Reference ranges for serum periostin in a population without asthma or chronic obstructive pulmonary disease. Clin Exp Allergy 2016; 00:1–12.
122. Kanemitsu Y, Matsumoto H, Izuhara K et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013; 132:305–12.
123. Bhakta NR, Woodruff PG. Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev 2011; 242:220–32.
124. Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4 + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1123–32.
125. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6:1133–41.
126. Pene J, Chevalier S, Preisser L et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008; 180:7423–30.
127. McKinley L, Alcorn JF, Peterson A et al. TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice. J Immunol 2008; 181:4089–97.
128. Agache I, Ciobanu C, Agache C, Anghel M. Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med 2010; 104:1131–7.
129. Massoud AH, Charbonnier LM, Lopez D et al. An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells. Nat Med 2016; 22:1013–22.
130. Al Ramli W, Prefontaine D, Chouiali F et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009; 123:1185–7.
131. Doe C, Bafadhel M, Siddiqui S et al. Expression of the T helper 17-associated cytokines IL-17A and IL-17F in asthma and COPD. Chest 2010; 138:1140–7.
132. Wilson RH, Whitehead GS, Nakano H et al. Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. Am J Respir Crit Care Med 2009; 180:720–30.
133. Busse WW, Holgate S, Kerwin E et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188:1294–302.
134. Choy DF, Hart KM, Borthwick LA et al. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med 2015; 7:301ra129.
135. D'silva L, Cook RJ, Allen CJ et al. Changing pattern of sputum cell counts during successive exacerbations of airway disease. Respir Med 2007; 101:2217–20.
136. Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc Am Thorac Soc 2009; 6:256–9.
137. Zhang XY, Simpson JL, Powell H et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy 2014; 44:1137–45.
138. Chupp GL, Lee CG, Jarjour N et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007; 357:2016–27.
139. Konradsen JR, James A, Nordlund B et al. The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma. J Allergy Clin Immunol 2013; 132:328–35.
140. Santos CB, Davidson J, Covar RA, Spahn JD. The chitinase-like protein YKL-40 is not a useful biomarker for severe persistent asthma in children. Ann Allergy Asthma Immunol 2014; 113:263–6.
141. Heaney LG, Djukanovic R, Woodcock A et al. Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax 2016; 71:187–9.
142. Cosmi L, Maggi L, Santarlasci V et al. Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. J Allergy Clin Immunol 2010; 125:222–30.
143. Grigg J. Antibiotics for preschool wheeze. Lancet Respir Med 2016; 4:2–3.
144. Stokholm J, Chawes BL, Vissing NH et al. Azithromycin for episodes with asthma-like symptoms in young children aged 1–3 years: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2016; 4:19–26.
145. Payne D, Bush A. Phenotype-specific treatment of difficult asthma in children. Paediatr Respir Rev 2004; 5:116–23.
146. Jochmann A, Artusio L, Robson K et al. Infection and inflammation in induced sputum from preschool children with chronic airways diseases. Pediatr Pulmonol 2016; 51:778–86.
147. Meijer RJ, Postma DS, Kauffman HF et al. Accuracy of eosinophils and eosinophil cationic protein to predict steroid improvement in asthma. Clin Exp Allergy 2002; 32:1096–103.
148. Szefler SJ, Phillips BR, Martinez FD et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233–42.
149. Hanania NA, Wenzel S, Rosen K et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187:804–11.
150. Sverrild A, Malinovschi A, Porsbjerg C et al. Predicting airway hyperreactivity to mannitol using exhaled nitric oxide in an unselected sample of adolescents and young adults. Respir Med 2013; 107:150–2.
151. Song JS, You JS, Jeong SI et al. Serum periostin levels correlate with airway hyper-responsiveness to methacholine and mannitol in children with asthma. Allergy 2015; 70:674–81.
152. Bentley JK, Chen Q, Hong JY et al. Periostin is required for maximal airways inflammation and hyperresponsiveness in mice1. J Allergy Clin Immunol 2014; 134:1433–42.
153. Birrell MA, Battram CH, Woodman P et al. Dissociation by steroids of eosinophilic inflammation from airway hyperresponsiveness in murine airways. Respir Res 2003; 4:3.
154. Tournoy KG, Kips JC, Schou C, Pauwels RA. Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness. Clin Exp Allergy 2000; 30:79–85.
155. Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973–84.
156. Gonem S, Berair R, Singapuri A, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2016; 4:699–707.
157. Saude EJ, Skappak CD, Regush S et al. Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy. J Allergy Clin Immunol 2011; 127:757–64.
158. Hargreave FE, Nair P. Point: is measuring sputum eosinophils useful in the management of severe asthma? Yes. Chest 2011; 139:1270–3.
159. Corren J. Inhibition of interleukin-5 for the treatment of eosinophilic diseases. Discov Med 2012; 13:305–12.
160. Hamilton JD, Suarez-Farinas M, Dhingra N et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2014; 134:1293–300.
161. Briasoulis O, Breckenridge R, Nunn A. External validity of trials should be taken into account before asthma drug candidates reach market authorisation. Lancet Respir Med 2016; 4:601–3.
162. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016; 375:65–74.
163. Soler M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254–61.
164. Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60:309–16.
165. Hanania NA, Alpan O, Hamilos DL et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154:573–82.
166. Castro M, Zangrilli J, Wechsler ME et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3:355–66.
167. Bjermer L, Lemiere C, Maspero J et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest 2016; 150:789–98.
168. Corren J, Weinstein S, Janka L et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 2016; 150:799–810.
169. Ortega HG, Liu MC, Pavord ID et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371:1198–207.
170. Bel EH, Wenzel SE, Thompson PJ et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189–97.
171. Bleecker ER, FitzGerald JM, Chanez P et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2 agonists: a randomised, multicentre, placebo-controlled phase III trial. Lancet 2016; 388:2115–17.
172. Castro M, Wenzel SE, Bleecker ER et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2:879–90.
173. FitzGerald JM, Bleecker E, Nair P et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388:2128–41.
174. Hanania NA, Korenblat P, Chapman KR et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 2016; 4:781–96.
175. Brightling CE, Chanez P, Leigh R et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015; 3:692–701.
176. Wenzel S, Ford L, Pearlman D et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:2455–66.
177. Wenzel S, Castro M, Corren J et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 2016; 388:31–44.